5-O-Acetyl-Renieramycin T from Blue Sponge Xestospongia sp. Induces Lung Cancer Stem Cell Apoptosis
暂无分享,去创建一个
[1] N. Saito,et al. Construction of the Pentacyclic Core and Formal Total Synthesis of (rac)‐Renieramycin T , 2018, ChemistryOpen.
[2] Glauber C. Brito,et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance , 2018, EMBO reports.
[3] Wipa Chantarawong,et al. Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds , 2018, AntiCancer Research.
[4] Mei Li,et al. Utilization of lung cancer cell lines for the study of lung cancer stem cells , 2018, Oncology letters.
[5] T. S. Ramasamy,et al. Cancer stem cells as key drivers of tumour progression , 2018, Journal of Biomedical Science.
[6] Ita Novita Sari,et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment , 2018, Stem cells international.
[7] Yue Yang,et al. CD44 promotes cell proliferation in non-small cell lung cancer , 2018, Oncology letters.
[8] Junfei Jin,et al. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer , 2017, Anti-cancer drugs.
[9] Ashish S. Bodhade,et al. Cancer stem cells: An insight , 2017, Journal of oral and maxillofacial pathology : JOMFP.
[10] P. Chanvorachote,et al. Chemistry of Renieramycins. 17. A New Generation of Renieramycins: Hydroquinone 5-O-Monoester Analogues of Renieramycin M as Potential Cytotoxic Agents against Non-Small-Cell Lung Cancer Cells. , 2017, Journal of natural products.
[11] W. Guo,et al. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity , 2017, Cell Death & Disease.
[12] V. Pongrakhananon,et al. Suppression of cancer stem-like phenotypes in NCI-H460 lung cancer cells by vanillin through an Akt-dependent pathway. , 2017, International journal of oncology.
[13] J. Hao,et al. Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment , 2017, Stem cells international.
[14] H. Sasano,et al. Bcl‐2 family in non‐small cell lung cancer: its prognostic and therapeutic implications , 2017, Pathology international.
[15] Y. Ba,et al. Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. , 2017, Oncology letters.
[16] I. Singh,et al. Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015) , 2017, Expert opinion on therapeutic patents.
[17] Robert M. Williams,et al. Stereoselective Total Synthesis of (-)-Renieramycin T. , 2016, The Journal of organic chemistry.
[18] K. O'Byrne,et al. Lung cancer stem cells: The root of resistance. , 2016, Cancer letters.
[19] W. Matsui. Cancer stem cell signaling pathways , 2016, Medicine.
[20] S. Luanpitpong,et al. Nitric Oxide and Aggressive Behavior of Lung Cancer Cells. , 2015, Anticancer research.
[21] Zhanguo Zhang,et al. MAPK/ERK Activation Sensitizes MKN-28 Cells to Cisplatin-Induced Apoptosis , 2015 .
[22] Martina Müller,et al. p53 Family and Cellular Stress Responses in Cancer , 2014, Front. Oncol..
[23] P. Tchounwou,et al. Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.
[24] S. Goodison,et al. Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway , 2014, Oncogene.
[25] M. Nishimura,et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers , 2014, International Journal of Clinical Oncology.
[26] V. Pongrakhananon,et al. Acquired resistance to chemotherapy in lung cancer cells mediated by prolonged nitric oxide exposure. , 2013, Anticancer research.
[27] H. Motaln,et al. Lung cancer stem cells: a biological and clinical perspective , 2013, Cellular Oncology.
[28] Yong-zhong Wu,et al. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. , 2013, International journal of molecular medicine.
[29] K. O'Byrne,et al. Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature , 2013, PloS one.
[30] M. Huang,et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. , 2013, Cancer research.
[31] Michael V. Fiandalo,et al. Caspase control: protagonists of cancer cell apoptosis. , 2012, Experimental oncology.
[32] G. Concepcion,et al. Chemistry of renieramycins. Part 13: Isolation and structure of stabilized renieramycin type derivatives, renieramycins W–Y, from Philippine blue sponge Xestospongia sp., pretreated with potassium cyanide , 2012 .
[33] Xiaochu Yan,et al. Nanog regulates self‐renewal of cancer stem cells through the insulin‐like growth factor pathway in human hepatocellular carcinoma , 2012, Hepatology.
[34] Fang Yuan,et al. Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells , 2012, Molecular Cancer.
[35] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[36] Y. Liu,et al. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. , 2012, Journal of pharmacological sciences.
[37] Julian Downward,et al. RAS Interaction with PI3K: More Than Just Another Effector Pathway. , 2011, Genes & cancer.
[38] B. Zhou,et al. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters , 2011, BMC Cancer.
[39] James W. Tung,et al. Non-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties , 2010, PloS one.
[40] J. Waldrep,et al. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. , 2010, Anticancer research.
[41] F. Qiu,et al. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. , 2010, Carcinogenesis.
[42] I. Herr,et al. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients , 2009, International journal of cancer.
[43] L. Mariani,et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.
[44] K. Suwanborirux,et al. Chemistry of renieramycins. Part 7: Renieramycins T and U, novel renieramycin–ecteinascidin hybrid marine natural products from Thai sponge Xestospongia sp. ☆ , 2009 .
[45] T. Owa,et al. Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues. , 2009, Bioorganic & medicinal chemistry.
[46] D. Newman,et al. Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.
[47] P. Schultz,et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations , 2009, Proceedings of the National Academy of Sciences.
[48] T. Molinski,et al. Drug development from marine natural products , 2009, Nature Reviews Drug Discovery.
[49] Alexei Vazquez,et al. The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.
[50] Anna E. Lokshin,et al. Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.
[51] M. Schuler,et al. Targeting BCL‐2 family proteins to overcome drug resistance in non‐small cell lung cancer , 2007, International journal of cancer.
[52] Michael F Clarke,et al. The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.
[53] K. Vousden,et al. Coping with stress: multiple ways to activate p53 , 2007, Oncogene.
[54] Eddie Reed,et al. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). , 2004, Oncology reports.
[55] K. Suwanborirux,et al. Chemistry of renieramycins. Part 5. Structure elucidation of renieramycin-type derivatives O, Q, R, and S from thai marine sponge Xestospongia species pretreated with potassium cyanide. , 2004, Journal of natural products.
[56] K. Suwanborirux,et al. Chemistry of renieramycins. Part 3.(1) isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide. , 2003, Journal of natural products.
[57] Robin M. Williams,et al. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. , 2002, Chemical reviews.
[58] P. Krammer,et al. Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines , 2002, International journal of cancer.
[59] Scott W. Lowe,et al. Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.
[60] N. Holbrook,et al. Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.
[61] E. Yazlovitskaya,et al. Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin* , 2000, The Journal of Biological Chemistry.
[62] P. Proksch,et al. Bioactive isoquinoline quinone from an undescribed Philippine marine sponge of the genus Xestospongia , 1996 .